Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab vs dacarbazine in untreated unresectable or metastatic melanoma
CTR20180025Phase 3Completed
- Sponsor
- Junshi Biosciences
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in melanoma, sponsored by Junshi Biosciences. Started Jan 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20180025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180025.